Test Page (do not delete)
December 2023
GRASP Reception Registration
Attending the 2023 San Antonio Breast Cancer Symposium (SABCS) in person? Join us for a reception bringing together scientists and patient advocates. All advocates, scientists, and partners are invited to connect and mingle in person at this fun event put on by GRASP, a new tradition at SABCS! The event will take place on-site at […] ...
SABCS23 GRASP Training
Join us for a training session so that you can be prepared for your upcoming event. Whether joining as a GRASP scientist, poster author, mentor, or patient advocate, these sessions will help you understand your respective role. ...
San Antonio Breast Cancer Symposium (SABCS23)
The 2023 San Antonio Breast Cancer Symposium (SABCS) will be held on December 5-9, 2023. This year’s SABCS conference will be held as a hybrid conference with both in-person events and live web streaming. The Symposium aims to achieve a balance of clinical, translational, and basic research, providing a forum for interaction, communication, and education for a […] ...
Group 1A: Inflammatory Breast Cancer; Triple Negative Breast Cancer; Black Populations Sold Out
Poster #PS18-09: The DARC side of breast cancer – DARC, Duffy-null and African ancestry influence in the triple negative breast cancer tumor microenvironment. Poster #PO2-09-05: Building genomic and transcriptomic data among African American and Black patients with triple-negative inflammatory breast cancer. ...
Group 1B: HER2-low, HER2-0, & HR+ Breast Cancer; Clinical Trials Sold Out
Poster #PO1-05-12: Pooled clinical trial data analyses comparing the biology of HER2-low vs HER2-0 breast cancer in patients with metastatic breast cancer following treatment with standard single agent chemotherapy. Poster #PO2-20-02: A Phase 3 study of gedatolisib plus fulvestrant with and without palbociclib in patients with HR+/ HER2- advanced breast cancer previously treated with a […] ...
Group 1C: BRCA+ Breast Cancer; Clinical Trials; Oncofertility; Younger Populations
Poster #PO2-11-06: Anti-Müllerian hormone in Young women with breast CAncer to predict permanent loss of ovarian function after chemotherapy and anti-HER2 therapy (AMYCA): a biomarker analysis of the BETH and KAITLIN trials. Poster #PO1-06-09: Phase 2 Trial with safety run-in of gedatolisib plus talazoparib in advanced triple negative or BRCA1/2+, HER2-negative breast cancers Big Ten […] ...
Group 1D: Brain Metastasis; Novel Targets
Poster #PS11-06: Analysis of HER2 expression changes from breast primary to brain metastases including HER2 Low and impact on overall survival. Poster #PO3-06-12: Targeting fatty acid synthase in brain metastatic triple-negative breast cancer. ...
Group 1E: ER+ Breast Cancer; Younger Populations; Quality of Life
Poster #PO2-12-01: Five-year quality of life (QOL) trajectories among young breast cancer (BC) survivors. Poster #PO4-01-11: Ovarian function suppression (OFS) use beyond five years?: Young breast cancer patient preferences. ...
Group 1F: HER2+ Breast Cancer; Triple Positive Breast Cancer; Clinical Trials; Treatment Resistance Sold Out
Poster #PS09-08: Genomic characterization of endocrine resistance in ER+HER2+ breast cancers in the POETIC Trial. Poster #PO2-04-06: Investigation of the genomic evolution of HER2-positive breast cancer following progression on dual HER2-targeted therapy with trastuzumab and tucatinib. ...
Group 2A: Lobular Breast Cancer; Imaging Sold Out
Poster #PO2-07-09: Early stage invasive lobular breast cancer is underestimated on conventional imaging including MRI. Poster #PO4-02-12: MDA iLobular prognostic pool: A novel approach for risk stratification in invasive lobular carcinoma. ...
Group 2B: Triple Negative Breast Cancer; Clinical Trials; Side Effects
Poster #PO2-12-12: REaCT 5G: A randomized study comparing bone pain after 5 days of filgrastim or one day of pegfilgrastim for primary febrile neutropenia prophylaxis during neo-/adjuvant chemotherapy for early breast cancer. Poster #PO1-18-07: Phase I trial of combination pembrolizumab and ruxolitinib in metastatic triple negative breast cancer. ...
Group 2C: HER2+, HER2-low, & Triple Negative Breast Cancer; Clinical Trials; Antibody-drug Conjugates
Poster #PS08-09: Impact of HER2 expression dynamics on the real-world activity of trastuzumab deruxtecan for metastatic breast cancer (RELIEVE). Poster #PO1-19-10: Durvalumab + datopotamab deruxtecan in patients with PD-L1 positive advanced/metastatic triple-negative breast cancer: Arm 8 of the phase 1b/2, open label, platform BEGONIA study. ...
No event found!
